ArticleScientific reports2025
Single cell RNAseq signatures refined with combiroc enhance identification of NK cells in blood and solid tissues.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cytotoxic CD8 T lymphocytes (CTLs) and natural killer (NK) cells share the common objective of controlling infections and detecting and removing tumor cells, albeit through distinct target recognition mechanisms. Although CTLs belong to the adaptive immune system and NK cells are innate lymphoid cells, they frequently exhibit considerable overlap in their molecular phenotypes. This overlap, as with many others in cell biology, poses challenges for distinguishing cells in the context of single cell transcriptomics. Building on a previous ROC-driven combinatorial approach, we developed a new computational framework for single-cell RNA-seq with the combiroc R package, and in this study we showed that it can identify non-canonical marker combinations for NK cells in Peripheral Blood Mononuclear Cell datasets. These combinatorial markers were in line with the Human Protein Atlas and we validated them through cytometry staining and functional assays. Markers selected with combiroc exhibit exceptional discriminatory power for identifying NK cells, both in blood and solid tumoral tissues. Besides this finding, we showed that our approach vastly optimizes standard differential expression signatures: it reduces dimensionality while improving interpretability and transferability to diagnostic applications, offering a practical solution for refining immune cell identities in complex transcriptomic datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.